sellModerate cluster of 6
Jonathan Young sold $27k of AKRO
Chief Operating Officer at Akero Therapeutics, Inc.. 607 shares at an average of $44.88, traded Mar 12, 2025, filed Mar 14, 2025.
Warning score
40Value
$27k
607 shares
Holdings after
200,540
-0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +20RoleCOO
- +5Trade size$27k at market
- 0Share of holdings soldSold 0.3% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-039745, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 12, 2025 | SOpen-market sale Common Stock | -607 | $44.88 | $27k | 200,540 | Mar 14, 2025 |
Related signals
Other insiders at Akero Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $1.4M 31,796 shares | -6% | |
| 30Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $24k 553 shares | -0% | |
| 42Moderate | Akero Therapeutics, Inc. | William Richard White Chief Financial Officer | $28k 659 shares | -1% | |
| 35Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $28k 659 shares | -1% | |
| 40Moderate | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $25k 586 shares | -0% | |
| 14Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $552k 12,500 shares | -7% | |
| 19Weak | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $576k 12,500 shares | -6% | |
| 45Moderate | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $1.5M 30,000 shares | -6% | |
| 19Weak | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $597k 12,500 shares | -6% | |
| 31Weak | Akero Therapeutics, Inc. | Jane Henderson director | $142k 3,000 shares | -24% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.